Ozempic vs Krispy Kreme: Wall Street firm bets weight-loss drugs won’t beat doughnut sales
Banking And Finance,Stock Market,Wall Street,Ozempic,Food,Public Health,Prescription Drugs
From the Right
AllSides Media Bias Rating: Lean Right
While the demand for weight loss drugs continues to surge, one Wall Street firm is betting that Americans' love for doughnuts is too strong to give them up.
Truist Securities on Monday upgraded Krispy Kreme to buy from hold, with analysts led by Bill Chappell saying that the negative impact of the glucagon-like peptide 1 (GLP-1) drugs has already been reflected in the stock's current valuation.
Check for Bias
The AI-powered AllSides Bias Checker instantly reveals the bias of a news article. Tap the button to use.
AllSides Picks
Red Blue Translator
Great Depression (The)
Headline Roundup
China Helped Iran Target US Military Base - WSJ
September 14th, 2026
Headline Roundup
Scotland, Wales, Northern Ireland Leaders to Meet to Begin Dissolution of UK - The Telegraph
September 13th, 2026
News
What the Media Missed: Children Recovered, Heat Deaths Soared, and More
Malayna J. Bizier
September 12th, 2026
